Showing results (251-260 of 343) with videos related to

Sort By:
Pageof 35
European Journal of Cancer (Oxford, England : 1990)|October 22, 2013
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancerF Loupakis, C Cremolini, L Salvatore, et al.
British Journal of Cancer|September 24, 2009
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)C Pinto, F Di Fabio, C Barone, et al.
The Pharmacogenomics Journal|February 24, 2010
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecanF Graziano, E Canestrari, F Loupakis, et al.
American Journal of Respiratory Cell and Molecular Biology|January 28, 1999
Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammationC G Garlisi, T T Kung, P Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2018
Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD databaseK L van Rooijen, Q Shi, K K H Goey, et al.
British Journal of Cancer|March 5, 2009
Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapyV Catalano, F Loupakis, F Graziano, et al.
Proceedings. Biological Sciences|July 5, 2013
Blue whales respond to simulated mid-frequency military sonarJeremy A Goldbogen, Brandon L Southall, Stacy L DeRuiter, et al.
British Journal of Cancer|August 30, 2008
Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapyF Graziano, A Ruzzo, F Loupakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2013
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)L Fornaro, S Lonardi, G Masi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trialsM D Berger, S Stintzing, V Heinemann, et al.
Pageof 35